OWC Pharmaceutical Research Corp (OWCP)

[Hercules1]

Dear Shareholder,
OWC Pharmaceutical Research Corporation (OWCP) is pleased to provide you with an update on the progress we made during 2016. We also are excited to present our goals and objective for the upcoming 2017.
OWC Pharmaceutical Research (OWCP) owns 100 percent of Israel-based One World Cannabis Ltd ("One World"). One World was formed to apply pharmaceutical research protocols and disciplines to the global medical cannabis industry.
The formation of One World has enabled OWCP to take advantage of Israel's role as the global center of medical cannabis research. In 2003, Israel was the second country to formally approve the use of medical cannabis. One World provides OWC with global access to the top research facilities and researchers in medical cannabis.
OWC Pharmaceutical's Management Team 
Key to OWCP's success is its management team, which I'm pleased to lead.
Dr. Yehuda Baruch is One World's Director of Research and is OWC's Chief Science Officer. Before joining OWC, Dr. Baruch was the head of the Israeli Ministry of Health's Medical Cannabis Program for ten years, where his responsibilities included overseeing the government's regulatory compliance, obtaining approvals for clinical trials from institutional review boards and overseeing patient cannabis approvals and dosage recommendations.
Ziv Turner is OWCP's VP Business Developmentand Managing Director of One World, our Israeli-based subsidiary.  Mr. Turner has over 20 years of experience in international sales, business development and management.
Mr. Alon Sinaiis the Chief Operating Officer of One World, is a retired Lt. Colonel of the Israel Defense Forces, medical division. He has 25 years of experience in the medical field and has responsibility for OWCP's research and development activities
Mr. Shmuel De Saban is OWCP's Chief Financial Officer. Mr. De Saban is an Israeli certified public account and has more than 20 years of financial services experience including an extensive background with early-stage companies.
Lastly, myself, Mordechai Bignitz. I'm a Certified Public Accountant in Israel with more than 40 years of business and financial experience and have held senior positions with biotech and pharmaceutical companies. I also served as chairman of the Investment Committee for Migdal Capital Markets, which at the time was Israel's largest private financial institution.
Our entire management team together with scientific research team has contributed to OWCP's success in achieving our goals last year. Our team's common objective is to enable the Company reach the goals and objectives it has outlined for 2017 and future years.
OWC Pharmaceutical Research's Business Model 
In 2015 we defined our business model, prioritized our opportunities and objectives, and established the infrastructure necessary to achieve OWCP's goals.


 We focused on several primary business and scientific goals.



First, our desire to bring Israel cannabis science to U.S. state-licensed businesses and to Europe, Canada and South America.  
Longer-term, OWCP's objective is to obtain approvals for cannabinoid-based drugs in North America and Europe, including trials under U.S. Food and Drug Administration ("FDA") protocols. Upon receipt of regulatory approval, which we are actively pursuing, our cannabinoid-based drugs would be available through traditional pharmaceutical distribution channels, including pharmacies to treat a wide variety of medical conditions.  
The effective delivery of cannabinoid-based drugs requires optimal delivery systems. We are furthering the development of our proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis, which we anticipate using for future trials for multiple myeloma, Post-Traumatic Stress Disorder ("PTSD"), and fibromyalgia


[URL=http://s1322.photobucket.com/user/spartacus120/media/november-1/one%20world-13_zpsg6fogqmm.jpg.html][/URL]